{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:12Z","timestamp":1793214612012,"version":"4.5.0"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Uveitis associated with Vogt-Koyanagi-Harada (VKH) disease is a bilateral, chronic, granulomatous autoimmune disease associated with vitiligo, poliosis, alopecia, and meningeal and auditory manifestations. The disease affects pigmented races with a predisposing genetic background. Evidence has been provided that the clinical manifestations are caused by a T-lymphocyte-mediated autoimmune response directed against antigens associated with melanocytes in the target organs. Alongside of T lymphocytes, autoreactive B cells play a central role in the development and propagation of several autoimmune diseases. The potential role of B lymphocytes in the pathogenesis of granulomatous uveitis associated with VKH disease is exemplified within several studies. The early initial-onset acute uveitic phase typically exhibits granulomatous choroiditis with secondary exudative retinal detachment and optic disc hyperemia and swelling, subsequently involving the anterior segment if not adequately treated. The disease eventually progresses to chronic recurrent granulomatous anterior uveitis with progressive posterior segment depigmentation resulting in \u201csunset glow fundus\u201d appearance and chorioretinal atrophy if not properly controlled. Chronically evolving disease is more refractory to treatment and, consequently, vision-threatening complications have been recognized to occur in the chronic recurrent phase of the disease. Conventional treatment with early high-dose systemic corticosteroids is not sufficient to prevent chronic evolution. Addition of immunomodulatory therapy with mycophenolate mofetil as first-line therapy combined with systemic corticosteroids in patients with acute initial-onset disease prevents progression to chronic evolution, late complications, vitiligo, and poliosis. Furthermore, patients under such combined therapy were able to discontinue treatment without relapse of inflammation. These findings suggest that there is a therapeutic window of opportunity for highly successful treatment during the early initial-onset acute uveitic phases, likely because the underlying disease process is not fully matured. It is hypothesized that early and aggressive immunosuppressive therapy will prevent remnant epitope generation in the initiation of the autoimmune process, the so-called primary response. B cell depleting therapy with the anti-CD20 monoclonal antibody rituximab is effective in patients with refractory chronic recurrent granulomatous uveitis. The good response after rituximab therapy reinforces the idea of an important role of B cells in the pathogenesis or progression of chronic recurrent uveitis associated with VKH disease.<\/jats:p>","DOI":"10.3389\/fmed.2021.705796","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T04:43:28Z","timestamp":1636692208000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["New Perspectives on the Immunopathogenesis and Treatment of Uveitis Associated With Vogt-Koyanagi-Harada Disease"],"prefix":"10.3389","volume":"8","author":[{"given":"Ahmed M.","family":"Abu El-Asrar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Struyf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghislain","family":"Opdenakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7323","DOI":"10.4049\/jimmunol.165.12.7323","article-title":"Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease","volume":"165","author":"Yamaki","year":"2000","journal-title":"J Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1006\/exer.2000.0893","article-title":"Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats","volume":"71","author":"Yamaki","year":"2000","journal-title":"Exp Eye Res."},{"key":"B3","first-page":"2004","article-title":"Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease","volume":"42","author":"Gocho","year":"2001","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B4","article-title":"Effect of immunosuppressive therapy on ocular blood flow in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease","volume-title":"Acta Ophthalmol","author":"Abu","year":"2021"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1167\/iovs.11-8984","article-title":"Optic disc swelling in Vogt-Koyanagi-Harada disease","volume":"53","author":"Nakao","year":"2012","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ophtha.2006.07.040","article-title":"Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients","volume":"114","author":"Yang","year":"2007","journal-title":"Ophthalmology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/02713680802233968","article-title":"Vogt-Koyanagi-Harada syndrome","volume":"33","author":"Fang","year":"2008","journal-title":"Curr Eye Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1111\/aos.12127","article-title":"Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids","volume":"91","author":"Abu","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/09273948.2019.1668430","article-title":"Incidence, risk factors and surgical outcomes of cataract among patients with Vogt-Koyanagi-Harada disease","volume":"29","author":"AlBloushi","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1111\/j.1755-3768.2012.02498.x","article-title":"The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease","volume":"90","author":"Abu","year":"2012","journal-title":"Acta Ophthalmol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/aos.13189","article-title":"Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease","volume":"95","author":"Abu","year":"2017","journal-title":"Acta Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1001\/archopht.1996.01100140384003","article-title":"Melanin-laden macrophages in cerebrospinal fluid in Vogt-Koyanagi-Harada syndrome","volume":"114","author":"Nakamura","year":"1996","journal-title":"Arch Ophthalmol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0039-6257(05)80105-5","article-title":"Vogt-Koyanagi-Harada syndrome","volume":"39","author":"Moorthy","year":"1995","journal-title":"Surv Ophthalmol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3109\/09273948.2016.1139730","article-title":"Chronic recurrent Vogt\u2013Koyanagi\u2013Harada disease and development of \u2018sunset glow fundus' predict worse retinal sensitivity","volume":"25","author":"Abu","year":"2017","journal-title":"Ocul Immunol Inflamm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/bjo.2007.128967","article-title":"Longitudinal quantification of aqueous flare and cells in Vogt-Koyanagi-Harada disease","volume":"92","author":"Fang","year":"2008","journal-title":"Br J Ophthalmol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ajo.2007.10.012","article-title":"Concomitant choroidal inflammation during anterior segment recurrence in Vogt-Koyanagi-Harada disease","volume":"145","author":"Bacsal","year":"2008","journal-title":"Am J Ophthalmol."},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.3109\/02713689008999417","article-title":"Immunohistochemical studies of Vogt-Koyanagi-Harada disease with sunset sky fundus","volume-title":"Curr Eye Res","author":"Inomata","year":"1990"},{"key":"B18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/eye.2008.89","article-title":"Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease","volume":"23","author":"Lai","year":"2009","journal-title":"Eye."},{"key":"B19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10792-008-9288-1","article-title":"Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease","volume":"30","author":"Kawaguchi","year":"2010","journal-title":"Int Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.it.2020.03.004","article-title":"Remnant epitopes generating autoimmunity: From model to useful paradigm","volume":"41","author":"Opdenakker","year":"2020","journal-title":"Trends Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/art.22353","article-title":"Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis","volume":"55","author":"Finckh","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B22","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1136\/annrheumdis-2012-203130","article-title":"What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review","volume":"73","author":"van Nies","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s10792-018-0949-4","article-title":"Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease","volume":"39","author":"Herbort CP","year":"2019","journal-title":"Int Ophthalmol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s00417-002-0538-z","article-title":"Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation","volume":"240","author":"Keino","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.ajo.2006.01.017","article-title":"Association between severity of inflammation in CNS and development of sunset glow fundus in Vogt-Koyanagi-Harada disease","volume":"141","author":"Keino","year":"2006","journal-title":"Am J Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10792-006-9009-6","article-title":"Spectrum of Vogt-Koyanagi-Harada disease in Singapore","volume":"27","author":"Chee","year":"2007","journal-title":"Int Ophthalmol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10792-006-9001-1","article-title":"The spectrum of Vogt-Koyanagi-Harada disease in Turkey: VKH in Turkey","volume":"27","author":"Tugal-Tutkun","year":"2007","journal-title":"Int Ophthalmol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00417-014-2904-z","article-title":"High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada disease treated with early high-dose corticosteroids","volume":"253","author":"Sakata","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1136\/bjophthalmol-2017-311691","article-title":"Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids","volume":"103","author":"Nakayama","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3109\/09273941003587541","article-title":"Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic Vogt-Koyanagi-Harada disease","volume":"18","author":"Cuchacovich","year":"2010","journal-title":"Ocul Immunol Inflamm."},{"key":"B31","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/09273940701624312","article-title":"The use of low-dose azathioprine in patients with Vogt-Koyanagi-Harada disease","volume":"15","author":"Kim","year":"2007","journal-title":"Ocul Immunol Inflamm."},{"key":"B32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/09273940500536766","article-title":"Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy","volume":"14","author":"Paredes","year":"2006","journal-title":"Ocul Immunol Inflamm."},{"key":"B33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ajo.2020.07.036","article-title":"Vogt-Koyanagi-Harada disease managed with immunomodulatory therapy within 3 months of disease onset","volume":"220","author":"Lin Oo","year":"2020","journal-title":"Am J Ophthalmol."},{"key":"B34","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.4049\/jimmunol.123.6.2890","article-title":"Evidence that thymocytes require at least two distinct signals to proliferate","volume":"123","author":"Beller","year":"1979","journal-title":"J Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0198-8859(97)00265-6","article-title":"HLA-DRB1*0405 is the predominant allele in Brazilian patients with Vogt-Koyanagi-Harada disease","volume":"59","author":"Goldberg","year":"1998","journal-title":"Hum Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1167\/iovs.04-1273","article-title":"T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and -negative Vogt-Koyanagi-Harada uveitis","volume":"46","author":"Damico","year":"2005","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B37","first-page":"956","article-title":"Absence of recognition of common melanocytic antigens by T cells isolated from the cerebrospinal fluid of a Vogt-Koyanagi-Harada patient","volume":"20","author":"Abad","year":"2014","journal-title":"Mol Vis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.autrev.2013.01.004","article-title":"Vogt-Koyanagi-Harada syndrome","volume":"12","author":"Greco","year":"2013","journal-title":"Autoimmun Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1080\/09273948.2018.1483520","article-title":"Vogt-Koyanagi-Harada disease associated with hepatitis B vaccination","volume":"27","author":"Sood","year":"2019","journal-title":"Ocul Immunol Inflamm."},{"key":"B40","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ajo.2005.06.020","article-title":"Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C","volume":"140","author":"Touitou","year":"2005","journal-title":"Am J Ophthalmol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/00006982-199616020-00013","article-title":"Detection of Epstein-Barr virus DNA by polymerase chain reaction in the vitreous from a patient with Vogt-Koyanagi-Harada syndrome","volume":"16","author":"Bassili","year":"1996","journal-title":"Retina."},{"key":"B42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/09273949609079639","article-title":"Analysis of herpes virus group (DNA) from cerebrospinal fluid in Vogt-Koyanagi-Harada disease","volume":"4","author":"Hotta","year":"1996","journal-title":"Ocul Immunol Inflamm."},{"key":"B43","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.antiviral.2019.06.004","article-title":"Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss","volume":"168","author":"Andrei","year":"2019","journal-title":"Antiviral Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/3-540-30791-5_1","article-title":"Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept","volume":"296","author":"Oldstone","year":"2005","journal-title":"Curr Top Microbiol Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10792-006-9020-y","article-title":"Cross-reaction between tyrosinase peptides and cytomegalovirus antigen by T cells from patients with Vogt-Koyanagi-Harada disease","volume":"27","author":"Sugita","year":"2007","journal-title":"Int Ophthalmol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1167\/iovs.16-19758","article-title":"The cytokine interleukin-6 and the chemokines CCL20 and CXCL13 are novel biomarkers of specific endogenous uveitic entities","volume":"57","author":"Abu","year":"2016","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1167\/iovs.17-23225","article-title":"Differential CXC and CX3C Chemokine expression profiles in aqueous humor of patients with specific endogenous uveitic entities","volume":"59","author":"El-Asrar","year":"2018","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/09273948.2019.1604974","article-title":"Local cytokine expression profiling in patients with specific autoimmune uveitic entities","volume":"28","author":"Abu","year":"2020","journal-title":"Ocul Immunol Inflamm."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1111\/aos.13835","article-title":"The CC chemokines CCL8, CCL13 and CCL20 are local inflammatory biomarkers of HLA-B27-associated uveitis","volume":"97","author":"Abu","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e780","DOI":"10.1111\/aos.14039","article-title":"Expression of interleukin (IL)-10 family cytokines in aqueous humour of patients with specific endogenous uveitic entities: elevated levels of IL-19 in human leucocyte antigen-B27-associated uveitis","volume":"97","author":"Abu","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/s41433-019-0693-7","article-title":"Soluble cytokine receptor levels in aqueous humour of patients with specific autoimmune uveitic entities: sCD30 is a biomarker of granulomatous uveitis","volume":"34","author":"Abu","year":"2020","journal-title":"Eye."},{"key":"B52","doi-asserted-by":"crossref","DOI":"10.1084\/jem.187.4.655","article-title":"B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1\/CXCR5","volume-title":"J Exp Med","author":"Legler","year":"1998"},{"key":"B53","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/35876","article-title":"B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1","volume":"391","author":"Gunn","year":"1998","journal-title":"Nature."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1093\/rheumatology\/keu163","article-title":"High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease","volume":"53","author":"Bugatti","year":"2014","journal-title":"Rheumatology."},{"key":"B55","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s13075-014-0434-z","article-title":"CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic 'window of opportunity'","volume":"16","author":"Greisen","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/cei.12439","article-title":"CXCL13 as a new biomarker of systemic lupus erythematosus and lupus nephritis \u2013 from bench to bedside?","volume":"179","author":"Schiffer","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10875-009-9325-5","article-title":"Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity","volume":"30","author":"Wong","year":"2010","journal-title":"J Clin Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1212\/WNL.0b013e3181c5b457","article-title":"Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS","volume":"73","author":"Sellebjerg","year":"2009","journal-title":"Neurology."},{"key":"B59","article-title":"Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment","volume-title":"Brain","author":"Krumbholz","year":"2006"},{"key":"B60","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jneuroim.2010.02.013","article-title":"Ectopic and high CXCL13 chemokine expression in myasthenia gravis with thymic lymphoid hyperplasia","volume":"221","author":"Shiao","year":"2010","journal-title":"J Neuroimmunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12865-015-0068-1","article-title":"CXCL13 antibody for the treatment of autoimmune disorders","volume":"16","author":"Klimatcheva","year":"2015","journal-title":"BMC Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jaut.2012.05.009","article-title":"The complexity of the BAFF TNF-family members: implications for autoimmunity","volume":"39","author":"Lahiri","year":"2012","journal-title":"J Autoimmun."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1097\/IAE.0000000000000506","article-title":"Sympathetic ophthalmia: clinicopathologic correlation in a consecutive case series","volume":"35","author":"Aziz","year":"2015","journal-title":"Retina."},{"key":"B64","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/sj.eye.6702342","article-title":"Expression of chemokines and gelatinase B in sympathetic ophthalmia","volume":"21","author":"Abu","year":"2007","journal-title":"Eye."},{"key":"B65","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3109\/09273949309085026","article-title":"Inflammatory cellular kinetics in sympathetic ophthalmia a study of 29 traumatized (exciting) eyes","volume":"1","author":"Shah","year":"1993","journal-title":"Ocul Immunol Inflamm."},{"key":"B66","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/0002-9394(88)90052-9","article-title":"Immunopathologic study of Vogt-Koyanagi-Harada syndrome","volume":"105","author":"Chan","year":"1988","journal-title":"Am J Ophthalmol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.coi.2016.09.003","article-title":"Targeting B cells in treatment of autoimmunity","volume":"43","author":"Franks","year":"2016","journal-title":"Curr Opin Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front Immunol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3389\/fimmu.2018.00622","article-title":"Cell Modulation Strategies in Autoimmune Diseases: New Concepts","volume":"9","author":"Musette","year":"2018","journal-title":"Front Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s10067-014-2781-1","article-title":"Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease","volume":"34","author":"Caso","year":"2015","journal-title":"Clin Rheumatol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3109\/14397595.2015.1071234","article-title":"Rituximab for sight-threatening refractory pediatric Vogt-Koyanagi-Harada disease","volume":"28","author":"Umran","year":"2018","journal-title":"Mod Rheumatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12348-011-0027-9","article-title":"Rituximab in refractory Vogt-Koyanagi-Harada disease","volume":"1","author":"Dolz-Marco","year":"2011","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2020.1820531","article-title":"Efficacy of B cell depletion therapy with rituximab in refractory chronic recurrent uveitis associated with Vogt-Koyanagi-Harada disease","volume":"29","author":"Abu","year":"2020","journal-title":"Ocul Immunol Inflamm."},{"key":"B74","doi-asserted-by":"crossref","DOI":"10.1080\/09273948.2021.1880604","article-title":"Efficacy of rituximab treatment in Vogt-Koyanagi-Harada disease poorly controlled by traditional immunosuppressive treatment","volume-title":"Ocul Immunol Inflamm.","author":"Bolletta","year":"2021"},{"key":"B75","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.705796\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T01:32:29Z","timestamp":1673746349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.705796\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,12]]},"references-count":75,"alternative-id":["10.3389\/fmed.2021.705796"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.705796","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,12]]},"article-number":"705796"}}